Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.

OBJECTIVE To determine long-term survival and predictors of recurrence in patients with platinum-treated ovarian cancer who were followed for 10 years after second-look laparotomy with negative findings. METHODS Records were reviewed of 91 consecutive patients with negative findings on second-look laparotomy after platinum-based chemotherapy between January 1978 and January 1987. Statistical analysis used Kaplan-Meier survival curves, Cox proportional hazards, and multiple logistic regression. RESULTS Mean age of patients was 57 (range 30-79) years. Distribution by stage and grade was as follows: stage I, ten; II, 18; III, 57; IV, six; grade 1, 18; 2, 28; 3, 45. Forty-seven of 91 women had optimal initial cytoreduction. Recurrence-free survival rates for all subjects were 75% at 2 years, 55% at 5 years, and 52% at 10 years. For women with stage I disease, the recurrence-free survival rate was 90% at 2, 5, and 10 years. For women with stage II disease, recurrence-free survival rates were 78, 72, and 66% at 2, 5, and 10 years, respectively. Patients with stage III or IV disease had recurrence-free survival rates of 72, 44, and 40% at 2, 5, and 10 years, respectively. Risk of recurrent disease was related to tumor stage (relative risk [RR] 2.02; 95% confidence interval [CI] 1.2, 3.3; P = .005), grade (RR 2.00; 95% CI 1.3, 3.2; P = .004), and presence of a residual tumor of more than 2 cm at the end of initial surgery (RR 3.19; 95% CI 1.2, 8.5; P = .02). CONCLUSION Ovarian cancer patients face an appreciable risk of recurrence in the first 5 years after second-look laparotomy with negative findings after platinum-based chemotherapy, but those who remain disease free at 5 years have excellent long-term survival rates. Tumor stage, grade, and presence of a residual tumor of more than 2 cm after initial surgery are significant predictors of recurrence.

[1]  D. Cox Regression Models and Life-Tables , 1972 .

[2]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.

[3]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[4]  P. Saigo,et al.  A review of second-look laparotomy for ovarian cancer. , 1986, Gynecologic oncology.

[5]  S. Rubin,et al.  Second-look surgery in ovarian carcinoma. , 1988, Critical reviews in oncology/hematology.

[6]  J. Barter,et al.  Second-look laparotomy. , 1994, Seminars in surgical oncology.

[7]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[8]  F. Parazzini,et al.  Survival of women with advanced ovarian cancer and complete pathologic response at second‐look laparotomy , 1996, Cancer.

[9]  P. Saigo,et al.  Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. , 1991, Gynecologic oncology.

[10]  S. Rubin,et al.  Second-Look Laparotomy in Stage I Ovarian Cancer Following Comprehensive Surgical Staging , 1993, Obstetrics and gynecology.

[11]  P. Bruzzi,et al.  Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy , 1995 .

[12]  J. Cain,et al.  Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. , 1988, American journal of obstetrics and gynecology.